Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)			1 Months Ended	3 Months Ended			6 Months Ended		9 Months Ended		12 Months Ended
	May. 11, 2015 USD ($) $ / shares shares	Apr. 27, 2015	May. 31, 2015 USD ($)	Sep. 30, 2015 USD ($) Customer shares	Sep. 30, 2014 USD ($) Customer	Jun. 30, 2014 USD ($) $ / shares	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($) $ / shares	Sep. 30, 2015 USD ($) Customer shares	Sep. 30, 2014 USD ($) Customer	Dec. 31, 2014 USD ($) Customer shares
Significant Accounting Policies [Line Items]
Reverse stock split of outstanding common stock		0.0093
Common stock, at the initial public offering price per shares | $ / shares	$ 14.00
Gross proceeds from initial public offering									$ 47,654,190
Preferred stock, shares outstanding | shares				0					0		0
Maturity period of investments									less than one year
Allowance for Doubtful Accounts Receivable				$ 129,922					$ 129,922		$ 85,068
Bad debt expense, net of recoveries				11,000	$ 15,000				44,854	$ 117,467
Change in inventory valuation reserves				62,872	(536,119)				273,752	(536,119)
Reclassified equipment with a net book value											210,606
Depreciation and leasehold improvement amortization expense				174,390	120,506				473,799	349,518
Amortization expense for capitalized software costs				0	3,896				0	15,583
Accretion of preferred stock issuance costs				0	19,488				35,046	71,175
Overstated stock issuance cost immaterial amount						$ 137,094		$ 137,094
Overstated net loss per share attributable to common stockholders | $ / shares						$ 1.42		$ 1.42
Deferred financing costs				59,582					59,582		75,131
Deferred financing cost amortization expense				4,523	2,700				37,461	2,700
Debt instrument, amortization expense				51,481	46,867				229,232	141,551
Amortization of discount on convertible notes				0					90,222
Loss on settlement of convertible notes									705,217
Accretion of discount on NuvoGen obligation									229,232	141,551
Write off of deferred financing costs									53,611
Write off unamortized debt discount									651,606
Deferred offering costs, noncurrent				0					0		$ 1,300,000
Licenses revenue fees				0	0				0	0
Research and development				$ 1,309,573	$ 649,949				$ 2,951,009	$ 2,372,972
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer				3	3				2	3
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage				26.00%	19.00%				29.00%	12.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage				16.00%	19.00%				10.00%	10.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage				12.00%	5.00%					9.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer									2		1
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage									23.00%		31.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage									23.00%
Revenue from grants and contracts | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Sales revenue percentage				0.00%	27.00%				12.00%	32.00%
Invetech PTY Ltd. Agreement
Significant Accounting Policies [Line Items]
Research and development				$ 150,000					$ 150,000
Growth Term Loan A
Significant Accounting Policies [Line Items]
Debt instrument, amortization expense				$ 31,595	$ 16,125				$ 120,627	$ 16,125
Accretion of discount on NuvoGen obligation					16,125		$ 16,125
Convertible Notes
Significant Accounting Policies [Line Items]
Accretion of discount on NuvoGen obligation					$ 0					$ 0
Software and Software Development Costs
Significant Accounting Policies [Line Items]
Long-term asset, estimated life									3 years
Minimum
Significant Accounting Policies [Line Items]
Long-term asset, estimated life									3 years
Maximum
Significant Accounting Policies [Line Items]
Long-term asset, estimated life									5 years
IPO
Significant Accounting Policies [Line Items]
Issuance of common stock from initial public offering, shares | shares	3,570,000
Common stock, at the initial public offering price per shares | $ / shares	$ 14.00
Gross proceeds from initial public offering	$ 50,000,000
Net proceeds from initial public offering after underwriters' fees, commissions and offering costs	$ 45,400,000
Preferred stock, shares outstanding | shares				0					0
Reclassification of additional paid in capital with direct offering costs			$ 2,300,000
Over-Allotment Option
Significant Accounting Policies [Line Items]
Issuance of common stock from initial public offering, shares | shares	90,076
Proceeds from issuance of common stock	$ 1,300,000